This is a broad pipeline update across 5+ programs, not a single binary catalyst. The most near-term catalytic events are: 1) Opakalim Phase 2/3 focal epilepsy topline in 2H 2026, 2) Taldefgrobep Phase 2 obesity topline in 2H 2026, and 3) Initiation of Phase 3 pivotal trials for BHV-1300 (Graves) and BHV-1400 (IgAN) in mid-2026. The MoDE/TRAP degrader data are particularly novel and de-risking, showing deep biomarker reductions with clean safety in the first-ever clinical data for extracellular protein degraders in autoimmune disease patients. Monitor enrollment updates and DSMB reviews for the upcoming pivotal trials. The ADC platform (BHV-1510 endometrial expansion, BHV-1530 dose escalation) provides additional upside optionality.
Price Chart
Executive Summary
Biohaven reported multiple positive pipeline updates at its May 2026 R&D Day, including: 1) Opakalim (Kv7 activator) showed a 3-fold prolongation of time-to-2nd GTC seizure (141 vs 47 days) in a small IGE proof-of-concept study and a 54% responder rate in focal epilepsy OLE, both with exceptionally low CNS adverse event rates. 2) BHV-1300 MoDE degrader in Graves' disease achieved >80% mean reduction of pathogenic TSHR-IgG1 and normalized thyroid hormones (T4 at median 3 weeks, T3 at median 5 weeks) in a Phase 1b study; pivotal Phase 3 to begin mid-2026. 3) BHV-1400 TRAP degrader in IgA nephropathy achieved 60% mean reduction of Gd-IgA1 within hours and 70% within one month, with early improvements in eGFR, hematuria, and proteinuria; pivotal Phase 3 to begin mid-2026. 4) BHV-1510 (Trop2 ADC) combined with cemiplimab showed deep/durable responses in heavily pretreated solid tumors, including endometrial cancer, where an expansion cohort is enrolling. 5) BHV-1530 (FGFR3 ADC) continues dose escalation with no DLTs and early signs of activity. 6) BHV-8100 (PKM2 activator) initiated Phase 1 SAD/MAD with early safety/tolerability data. 7) Taldefgrobep alfa (myostatin/activin inhibitor for obesity) initiated Phase 2 with PK/PD interim data supporting weekly and monthly dosing; topline expected 2H 2026. The breadth of positive clinical updates across multiple wholly-owned platforms (Kv7, degrader, ADC, myostatin, PKM2) is significant but most data remain early-stage (Phase 1/Proof-of-Concept) with small sample sizes; pivotal endpoints and registration remain key risks.
Key Facts
- Opakalim 75 mg QD: median time to 2nd GTC seizure = 141 days vs 47 days placebo (3x, IGE PoC study, n=27)
- Opakalim 75 mg: 33% completed 24-week DB phase without 2nd GTC seizure vs 0% placebo; 20% seizure-free vs 0% placebo
- Opakalim 75 mg 6-month OLE in focal epilepsy (n>100): 54% achieved ≥50% seizure reduction over any consecutive 6 months
- Opakalim: no somnolence, dizziness, fatigue, or memory impairment in IGE study; dizziness 5.0% in focal OLE (vs 25% for competitor Kv7)
- BHV-1300 (Graves): >80% mean reduction of TSHR-IgG1 by week 12; Free T4 normalized at median 3 weeks, Free T3 at median 5 weeks (n=3 hyperthyroid patients)
- BHV-1300: no serious/severe AEs, no drug discontinuations, no significant cholesterol/albumin/LFT changes; preserved IgG3, IgA, IgE, IgM
- BHV-1300: pivotal Phase 3 in Graves disease to commence mid-2026 (double-blind, placebo-controlled, 26-week, primary endpoint: normal T3/T4/TSH off ATD)
- BHV-1400 (IgAN): 60% mean reduction of Gd-IgA1 within hours, 70% within one month of SC dosing (500 mg Q2WK)
- BHV-1400: hematuria 3+ resolved to trace/negative by Day 60; UPCR decreased; eGFR increased over one month dosing (n=10)
- BHV-1400: no serious/severe AEs, no drug discontinuations; preserved IgA, IgG, IgE, IgM
- BHV-1400: pivotal Phase 3 in IgAN to commence mid-2026 (double-blind, placebo-controlled, 52-week, n=420, primary: PCR, eGFR, Gd-IgA1)
- BHV-1510 (Trop2 ADC) + cemiplimab: responses in heavily pretreated solid tumors (87.1% prior anti-PD(L)1); endometrial cancer expansion cohort enrolling
- BHV-1530 (FGFR3 ADC): dose escalation continuing with no DLTs; early tumor reduction in FGFR3-altered and WT-overexpressing patients
- BHV-8100 (PKM2 activator): first-in-human SAD/MAD initiated 2Q 2026; no SAEs, most AEs mild/resolved
- Taldefgrobep alfa (obesity): Phase 2 PK/PD interim data supports 100 mg Q1W and 150 mg Q4W dosing (myostatin suppression >80%); topline 2H 2026
- >1,000 subjects dosed with opakalim across trials; >700 subjects dosed with taldefgrobep alfa across trials
Financial Impact
Pipeline progress de-risks multiple wholly-owned platform programs with blockbuster potential (epilepsy, Graves disease, IgAN, obesity, oncology ADCs). Phase 3 pivotal trials starting mid-2026 in Graves and IgAN represent major value inflection points.
Risk Factors
- All clinical data presented are from small, early-stage studies (Phase 1/PoC) — pivotal trial results may differ
- Opakalim IGE study terminated early (enrollment challenges), formal statistical testing not provided; efficacy signal is descriptive only
- BHV-1300 and BHV-1400 Phase 1b data are preliminary (n=3-10 patients); safety/efficacy durability beyond 12 weeks (BHV-1300) and 1 month (BHV-1400) not established
- BHV-1510 and BHV-1530 are early Phase 1; many ADC programs fail at dose optimization or later-stage testing
- Competition in epilepsy (azetukalner/XEN496, cenobamate), obesity (semaglutide, tirzepatide, orforglipron, bimagrumab), IgAN (sparsentan, VOYXACT, Tarpevo, mezagitamab), Graves (FcRn inhibitors) — market penetration is not assured
- Company has no approved products; all programs are clinical-stage — financing/dilution risk, though $1.5B market cap provides runway visibility
- Multiple simultaneous Phase 3 programs (opakalim, BHV-1300, BHV-1400, taldefgrobep) create significant execution risk and cash burn
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001935979-26-000048 |
| Exhibit: exhibit992may27thpressrele.htm | 0001935979-26-000048 |
| Exhibit: exhibit991may26thpressrele.htm | 0001935979-26-000048 |
| Document: bhvn-20260526.htm | 0001935979-26-000048 |
| Document: 0001935979-26-000048-index-headers.html | 0001935979-26-000048 |
| Document: 0001935979-26-000048-index.html | 0001935979-26-000048 |
| Document: 0001935979-26-000048.txt | 0001935979-26-000048 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $14.69 | awaiting T+5 | — | $13.88 (−5.51%) |
Oct 15, 2026 10d ago | 8-K | $10.78 $13.88 | ▲ +28.76% | ▲ +29.19% | $13.88 (+28.76%) |
Sep 9, 2026 6w ago | 8-K | $12.79 $13.89 | ▼ −8.60% | ▼ −9.10% | $13.88 (−8.52%) |
Aug 26, 2026 8w ago | 8-K | $16.95 $15.69 | ▼ −7.43% | ▼ −7.31% | $13.88 (−18.11%) |
Aug 10, 2026 10w ago | 8-K | $14.49 $13.57 | ▼ −6.35% | ▼ −5.95% | $13.88 (−4.21%) |
Jul 9, 2026 15w ago | 8-K | $15.55 $14.17 | ▼ −8.87% | ▼ −8.31% | $13.88 (−10.74%) |
May 27, 2026 21w ago | 8-K | $10.24 $11.40 | ▲ +11.33% | ▲ +11.01% | $13.88 (+35.55%) |
May 4, 2026 24w ago | 424B5 | $9.71 $9.20 | ▲ +5.25% | ▲ +7.24% | $13.88 (−42.95%) |
May 4, 2026 24w ago | S-3ASR | $9.71 $9.20 | ▼ −5.25% | ▼ −7.24% | $13.88 (+42.95%) |
May 4, 2026 24w ago | 8-K | $9.71 $9.20 | ▼ −5.25% | ▼ −7.24% | $13.88 (+42.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers